(Q41486707)

1 October 2017

1 reference

title

Is there a role for a pure noradrenergic drug in the treatment of depression? (English)

1 reference

1 October 2017

Montgomery SA

1

1 reference

1 October 2017

language of work or name

English

0 references

publication date

1 April 1997

1 reference

European Neuropsychopharmacology

1 October 2017

published in

1 reference

1 October 2017

volume

7 Suppl 1

1 reference

1 October 2017

page(s)

S3-9; discussion S71-3

1 reference

Effects of zimelidine and desipramine on serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Antidepressant response to tricyclics and urinary MHPG in unipolar patients. Clinical response to imipramine or amitriptyline

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Daily variations of the urine content of 3-methoxy-4-hydroxyphenylglycol in two manic-depressive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Urinary MHPG levels and tricyclic antidepressant drug selection. A preliminary communication on improved drug selection in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Urinary 4-hydroxy-3-methoxyphenylglycol is not a predictor for clinical response to amitriptyline in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Catecholamine metabolism in affective disorders. 3. MHPG and other catecholamine metabolites in patients treated with lithium carbonate

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Urinary Catecholamine Metabolites during Behavioral Changes in a Patient with Manic-Depressive Cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Noradrenaline in basic models of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

3-Methoxy-4-hydroxy phenylglycol (MHPG) excretion in depressive states. A pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Catecholamine Metabolism, Depressive Illness, and Drug Response

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Response to Amitriptyline and Urinary MHPG in Bipolar Depressive Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Failure to correlate urinary MHPG with clinical response to amitriptyline

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Toward a biochemical classification of depressive disorders. III: Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Catecholamine metabolism in affective disorders —IV. Preliminary studies of norepinephrine metabolism in depressed patients treated with amitriptyline

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

3-MHPG as a non-predictor of antidepressant response to imipramine and electroconvulsive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Antidepressant drugs and the emergence of suicidal tendencies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

Comparing SSRIs: From chemistry to clinical choice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900414-8

7 January 2021

10.1016/S0924-977X(97)00414-8

Identifiers

DOI

1 reference

1 October 2017

1 reference